BPH investee signs JV with cutting edge cannabis researcher
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
BPH Energy Limited (ASX:BPH) investee Patagonia Genetics SpA has entered into a joint venture agreement with Israeli based research group Bio-Sciences Pharma Ltd (BSP).
BSP is a subsidiary of Impact NRS (NRS) and is at the forefront of medical cannabis research in Israel. The company specialises in a Cannabis Cell Transformation Platform that combines cutting edge gene editing tools with advanced breeding technologies.
It owns over 1000 square meters of growing facilities comprising approximately 10,000 seedlings at all times, and over 200 square meters of state-of-the-art laboratories supporting metabolomics and tissue culture research, containing cutting-edge chemical and analytical equipment and tools.
The agreement will see BSP and Patagonia expedite the cultivation, testing and cataloguing of Patagonia’s genetic collection, as well as the commercialisation of any genetics that show unique medicinal properties.
BSP will conduct an 18 month study, with Patagonia supplying BSP with 94 cultivars for testing.
The study is designed to determine how each of more than 100 active compounds found in cannabis can interact within the Cannabis plant.
Once individual compounds and their effects have been characterised, gene expression in plants can be modified to produce the desired cannabinoids as well as negate any negative side effect.
Genetic samples will be propagated under BSP's cannabis cultivation license in Israel. A Certificate of Analysis (CoA) will be produced for each cultivar quantifying the cannabinoid and terpene profiles, including THC and cannabidiol CBD.
Once the study has been finalised, Patagonia and BSP will review the results with a view to co-commercialize any cultivars of interest.
"This is a landmark deal for Patagonia Genetics, Patagonia's in-country manager Miguel Serrano said.
“We will finally be able to explore the potential of our unique genetic collection. With up to 94 cultivars to be propagated and lab tested this deal saves Patagonia several years in research and development and significant capital expenditure.
“Patagonia considers Israel is the leading authority on medicinal cannabis research and is excited to collaborate with BSP in delivering a designer cannabis product. Having a catalogue of up to 94 lab tested cultivars will position Patagonia as one of the most diversified seed banks in the cannabis and hemp space.”
Patagonia has been busy over the last couple of months
In early December, Patagonia acquired the rights to a rare high CBD hemp strain known as the Carmangola Italian Hemp strain mainly grown for fibre production as well as for Cannabidiol (CBD) oil extraction and resin.
Carmagnola is a phenotype that carries a cannabinoid profile of 18.4% CBD and 0.11% THC.
Patagonia recently completed due diligence on Gibraltar-based Calpernia Planters Limited, which holds various licenses which permit it to import and export hemp and cannabis related genetic material, but with a limit on THC content of 0.3% or less.
Through an agreement with Calpernia, Patagonia can immediately begin selling this newly discovered genetic phenotype under Calpernia's hemp license.
It is expected to supply the market with genetic cuttings or clones of this phenotype by Q1 2020 and feminised seeds by Q3 2020.
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.
